Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-human interferon alpha receptor 1 monoclonal antibody and application thereof

A technology of monoclonal antibody and interferon α, applied in the direction of anti-cytokine/lymphokine/interferon immunoglobulin, application, antibody, etc., can solve problems such as unwanted side effects and nervous disorders, and achieve good clinical effects

Active Publication Date: 2021-08-20
QYUNS THERAPEUTICS CO LTD
View PDF46 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, IFNα treatment has been shown to cause undesired side effects in some cases, including fever and neurological disturbances
Therefore, there are pathological situations where inhibition of type I interferon activity may be beneficial to patients, and there is a need for drugs that effectively inhibit type I interferon activity

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-human interferon alpha receptor 1 monoclonal antibody and application thereof
  • Anti-human interferon alpha receptor 1 monoclonal antibody and application thereof
  • Anti-human interferon alpha receptor 1 monoclonal antibody and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0082] Example 1 Preparation of anti-human interferon alpha receptor 1 monoclonal antibody QX006N

[0083] Purchasing human interferon alpha receptor 1 (IFNAR1) from Shanghai Nearshore Technology Co., Ltd. for immunization of New Zealand rabbits, using B cell cloning technology to obtain antigen-binding specific antibody clones, and then screening for binding to human IFNAR1 and having human IFNAR1 inhibitory activity of monoclonal antibodies. First, the cell supernatant was detected by Binding ELISA, and the clones binding to human IFNAR1 were selected; then, the clones with human IFNAR1 inhibitory activity were selected for detection by HEK Blue IFNα / β reporter gene cell method. The above immunization and screening processes are entrusted to commercial companies.

[0084] 37 clones were selected for recombinant expression and sequenced. It was determined that 362# and 1203# had the best cell neutralizing activity, and the sequences of the two clones were very similar. The...

Embodiment 2

[0090] Embodiment 2 Equilibrium dissociation constant (K D ) determination

[0091] The affinity between QX006N (HZD1203-45-IgG4.1) and human IFNAR1 was detected by BiacoreT200, and all processes were carried out at 25°C. Using a commercial Protein A chip, an appropriate amount of antibody was immobilized by the capture method, so that the Rmax was around 50RU, and the capture flow rate was 10 μl / min. The antigen was serially diluted, the flow rate of the instrument was switched to 30 μl / min, and the concentration flowed through the reference channel and the channel of the immobilized antibody in order of concentration from low to high, and the buffer was used as a negative control. After each association and dissociation, the chip was regenerated with pH 1.5 glycine. Use the analysis software that comes with the instrument to select the 1:1 binding model in the Kinetics option for fitting, and calculate the binding rate constant k of the antibody a , the dissociation rate ...

Embodiment 3

[0096] Example 3QX006N and Anifrolumab neutralize human interferon-induced HEK Blue IFNα / β cell STAT1 / 2 phosphorylation activity

[0097] Use the HEK Blue IFNα / β reporter gene cell line to measure the phosphorylation activity of the intracellular signal molecule STAT1 / 2 mediated by QX006N antagonizing interferon through IFNAR1: the cells in the culture medium were divided into 4×10 per well 4 Cells were added to 96 wells and then incubated at 37°C and 5% CO 2 conditions overnight. Serial dilutions of antibody concentrations ranging from 0 to 5 μg / ml were added to the cells along with 0.2 ng / ml of IFNα.2b. Then at 37 °C and 5% CO 2 Cultivate under conditions for 24 hours, collect the cell culture supernatant and add 10% QUANTI-Blue TM Detection reagents at 37°C and 5% CO 2 React under the conditions for 1 hour, then detect the OD630nm value and draw the dose-response curve, and then analyze the antagonistic activity of the antibody. The dose-response curve is as follows: ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an anti-human interferon alpha receptor 1 (IFNAR1) monoclonal antibody and application thereof. The anti-human interferon alpha receptor 1 (IFNAR1) monoclonal antibody comprises three heavy chain complementary determining regions (CDR-H1, CDR-H2 and CDR-H3) and three light chain complementary determining regions (CDR-L1, CDR-L2 and CDR-L3). Wherein (a) the amino acid sequence of the CDR-H1 is as shown in SEQ ID NO: 1, (b) the amino acid sequence of CDR-H2 is as shown in SEQ ID NO: 2; (c) the amino acid sequence of the CDR-H3 is as shown in SEQ ID NO: 3; (d) the amino acid sequence of the CDR-L1 is as shown in SEQ ID NO: 4; (e) the amino acid sequence of the CDR-L2 is as shown in SEQ ID NO: 5; and (f) the amino acid sequence of the CDR-L3 is as shown in SEQ ID NO: 6. The affinity of the anti human interferon alpha receptor 1 (IFNAR1) monoclonal antibody for binding human IFNAR1 is equivalent to that of the anti human IFNAR1 monoclonal antibody Anifrolumab, the neutralizing activity of the anti-human IFNAR1 monoclonal antibody for binding with the human IFNAR1 monoclonal antibody at the cellular level is equivalent to that of the Anifrolumab, and the anti-human IFNAR1 monoclonal antibody is expected to show a good clinical effect in the aspect of preventing and treating related diseases.

Description

technical field [0001] The invention relates to the field of antibody medicine. Specifically, the present invention relates to monoclonal antibodies against human interferon alpha receptor 1 (IFNAR1) and applications thereof. Background technique [0002] Type I interferon (IFN) (IFNα, IFNβ, IFNω, IFNτ) is a family of structurally related cytokines that have antiviral, antitumor and immunomodulatory effects (Hardy et al., Blood.97:473, 2001; Cutrone and Langer, J. Biol. Chem. 276:17140, 2001). The human IFNα locus includes two subfamilies. The first subfamily consists of 14 non-allelic and 4 pseudogenes with at least 80% homology. The second subfamily (αII or ω) contains 5 pseudogenes and one functional gene, which show 70% homology to the IFNα gene (Weissmann and Weber, Prog.Nucl.AcidRes.Mol.Biol., 33:251 -300, 1986). The subtypes of IFNα have different specific activities, but they share the same biological landscape (Streuli et al., PNAS-USA78:2848, 1981) and have th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K16/24C12N15/13C12P21/08A61K39/395A61P37/02A61P25/00A61P3/10A61P1/00A61P29/00A61P17/06A61P5/00A61P19/02A61P13/12A61P31/18A61P37/06
CPCC07K16/249A61P37/02A61P25/00A61P3/10A61P1/00A61P29/00A61P17/06A61P5/00A61P19/02A61P13/12A61P31/18A61P37/06C07K2317/565C07K2317/56C07K2317/51C07K2317/515C07K2317/24C07K2317/76C07K2317/92A61K2039/505C07K16/2866
Inventor 裘霁宛陈卫孔永乔怀耀裘之华吴亦亮陈涛秦晓燕梁立业
Owner QYUNS THERAPEUTICS CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com